Berlin’s Apheris and Ginkgo bring pharma giants together to train AI on 10,000 antibodies

Introducing Apheris Foundry: federated drug discovery models, customized to your data and accessible to your agents

Affinity scores should depend on how a compound binds. ApherisAffinity uses structurally validated training data, a geometry-aware affinity head and disrupted-binding-site negatives, so its predictions respond to target changes and rank compounds in a real discovery series better than Boltz‑2 and Nesso‑1.

Apheris federated networks for drug discovery and European healthcare studies can now run on T-Systems’ sovereign infrastructure, with patient data staying inside each hospital.